Immunotherapy for prostate cancer: current status and future perspectives
10.3969/j.issn.1009-8291.2024.03.016
- VernacularTitle:免疫治疗在前列腺癌中应用的现状及展望
- Author:
Bangwei FANG
1
;
Yao ZHU
1
Author Information
1. Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
- Publication Type:Journal Article
- Keywords:
prostate cancer;
immunotherapy;
tumor immune microenvironment;
immune-checkpoint inhibitors;
cancer vaccines;
CAR-T
- From:
Journal of Modern Urology
2024;29(3):284-289
- CountryChina
- Language:Chinese
-
Abstract:
As an emerging cancer treatment modality, immunotherapy has shown promising efficacy in a variety of solid tumors, but it has failed to achieve a breakthrough in the treatment of prostate cancer.This review aims to provide an overview of the current applications of immunotherapy for prostate cancer, including immune-checkpoint inhibitors, cancer vaccines and chimeric antigen receptor T-cell (CAR-T), briefly describe the mechanisms of various immunotherapy modalities, summarize the results of clinical trials, and discuss the challenges and prospects.
